

Karyopharm Therapeutics Inc.  
Form 4  
November 25, 2014

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Chione Ltd

2. Issuer Name and Ticker or Trading Symbol  
Karyopharm Therapeutics Inc.  
[KPTI]

5. Relationship of Reporting Person(s) to Issuer  
  
(Check all applicable)

(Last) (First) (Middle)  
SIMOU MENARDOU 8, RIA  
COURT 8, OFFICE 101  
  
(Street)

3. Date of Earliest Transaction  
(Month/Day/Year)  
11/21/2014

\_\_\_ Director \_\_\_X\_\_\_ 10% Owner  
\_\_\_ Officer (give title below) \_\_\_ Other (specify below)

6015 LARNACA, G4

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
\_\_\_ Form filed by One Reporting Person  
\_X\_ Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) |   |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|--|---|
|                                 |                                      |  |                                | (A) or (D)  | Price   |  |  |   |
|                                 |                                      |  |                                | Code V  | Amount  |  |  |   |
| COMMON STOCK                    | 11/21/2014                           |  | S                              | 42,800  | D   | \$ 41.2884<br>(1) (2)                                    | 9,610,815<br>(3) (4) (5)                   | D |
| COMMON STOCK                    | 11/24/2014                           |  | S                              | 75,000  | D   | \$ 41.784<br>(1) (2)                                     | 9,535,815<br>(3) (4) (5)                   | D |
| COMMON STOCK                    | 11/25/2014                           |  | S                              | 53,173  | D   | \$ 42.5088   | 9,482,642                                  | D |
| COMMON STOCK                    | 11/25/2014                           |  | S                              | 61,326  | D   | \$ 43.5439   | 9,421,316                                  | D |
|                                 | 11/25/2014                           |  | S                              | 10,501  | D   |  | 9,410,815                                  | D |

Edgar Filing: Karyopharm Therapeutics Inc. - Form 4

COMMON  
STOCK

\$  
44.0349

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 3) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable   | Expiration Date   | Title                                      | Amount or Number of Shares  |

## Reporting Owners

**Reporting Owner Name / Address**

**Relationships**

Director    10% Owner    Officer    Other

Chione Ltd  
SIMOU MENARDOU 8  
RIA COURT 8, OFFICE 101  
6015 LARNACA, G4

X

Czernik Marcin  
SIMOU MENARDOU 8,  
RIA COURT 8, OFFICE 101  
6015 LARNACA, G4

X

Hadjimichael Andreas  
SIMOU MENARDOU 8,  
RIA COURT 8, OFFICE 101  
6015 LARNACA, G4

X

Hadjimichael Amalia  
SIMOU MENARDOU 8,  
RIA COURT 8, OFFICE 101  
6015 LARNACA, G4

X

Smolokowski Wiaczeslaw  
 CHALET LENOTCHKA CH.DE BARNOUD  
 1885 CHESIERES  
 SWITZERLAND, G4 00000

X

## Signatures

|  |            |
|--|------------|
| /s/ Chione Limited, by /s/ Simon Prisk, as attorney-in fact by power of attorney         | 11/25/2014 |
| __Signature of Reporting Person  | Date       |
| /s/ Marcin Czernik, by /s/ Simon Prisk, as attorney-in fact by power of attorney         | 11/25/2014 |
| __Signature of Reporting Person  | Date       |
| /s/ Andreas Hadjimichael, by /s/ Simon Prisk, as attorney-in fact by power of attorney   | 11/25/2014 |
| __Signature of Reporting Person  | Date       |
| /s/ Amalia Hadjimichael, by /s/ Simon Prisk, as attorney-in fact by power of attorney    | 11/25/2014 |
| __Signature of Reporting Person  | Date       |
| /s/ Wiaczeslaw Smolokowski, by /s/ Simon Prisk, as attorney-in fact by power of attorney | 11/25/2014 |
| __Signature of Reporting Person  | Date       |

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The prices reported in Column 4 are weighted average prices. The 42,800 shares referred to in the first row of Column 4 were sold at prices ranging from \$41.00 to \$41.88, inclusive. The 75,000 shares referred to in the second row of Column 4 were sold at prices ranging from \$41.50 to \$41.975, inclusive. . The 53,173 shares referred to in the third row of Column 4 were sold at prices ranging from \$42.00 to \$42.89, inclusive. The 61,326 shares referred to in the fourth row of Column 4 were sold at prices ranging from \$43.00 to \$43.99, inclusive. The 10,501 shares referred to in the fifth row of Column 4 were sold at prices ranging from \$44.00 to \$44.09, inclusive.
- (2) The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within each of the ranges set forth in footnote 1 above.
- (3) Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and Amalia Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione.
- (4) Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed, except, with respect to any person, to the extent of the pecuniary interest of such person in such securities.
- (5) Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.

### Remarks:

Edgar Filing: Karyopharm Therapeutics Inc. - Form 4

Exhibit Index Exhibit 24.1 - Power of Attorney, dated February 12, 2014, made by Marcin Czernik and Chione Limited in favor of Karyopharm Therapeutics Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.